Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine ’s harm, current knowledge deficits, clinical and harm reduction strategies for mi...

Source: Harm Reduction Journal - September 30, 2023 Category: Drugs & Pharmacology Authors: Claire M. Zagorski, Rebecca A. Hosey, Christopher Moraff, Aaron Ferguson, Mary Figgatt, Shoshana Aronowitz, Natalie E. Stahl, Lucas G. Hill, Zoe McElligott and Nabarun Dasgupta Tags: Perspective Source Type: research